Abstract

We welcome the recent article by Chen et al, which conducted an economic evaluation of pembrolizumab for patients with previously treated microsatellite instability-high solid tumors. We would like to congratulate the authors on a valuable research article, while highlighting methodological limitations and consequent biases that affect the robustness of the economic evaluation. We recognize that the research is presented as a case study to explore challenges in evaluating tumor-agnostic therapies. Nevertheless, we are concerned that the cost-effectiveness results for pembrolizumab may be misinterpreted and read out of context.